20 articles
A copper compound restored brain waste-clearance pumps, cutting toxic amyloid buildup by 42% and improving spatial memory by 44% in preclinical tests.
Epicrispr's GEMS platform silences disease genes epigenetically — reversibly and safely — with a single viral vector, targeting FSHD and beyond.
A large study confirms current CKD diagnostic thresholds hold up under gold-standard kidney testing, while revealing which biomarker combo predicts risk best.
Denali's Avlayah uses a novel transport platform to cross the blood-brain barrier, cutting CSF biomarkers by 91% in trials.
GSK acquires 35Pharma for $950M, gaining a drug that may treat lung disease while also improving insulin sensitivity and preserving muscle.
Japanese scientists engineered hybrid vitamin K molecules that are 3x more potent at regrowing neurons, potentially transforming Alzheimer's treatment.
A Kaiser Permanente program mailing HPV self-test kits raised cervical cancer screening rates by 2.2 percentage points, expanding access for overdue patients.
New research shows targeting ghrelin receptors improves muscle function and reduces sarcopenia in aging mice through better mitochondrial health.
Singapore researchers find calcium alpha-ketoglutarate repairs brain cell communication and restores early memory abilities in Alzheimer's models.
A placebo-controlled trial found daily MK-7 supplementation modestly reduced coronary artery calcification progression over two years.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
UK biotech secures MJFF grant to tackle GBA1 mutations — the most common genetic risk factor for Parkinson's — with a novel two-protein approach.
A 20,000-person study validates IgG glycans as aging biomarkers, with therapeutic plasma exchange reducing glycan age by 0.4 years per month.
Johns Hopkins researchers find that a protein producing 'rotten egg' gas in tiny amounts may protect memory and prevent brain damage.
ProJenX completes enrollment for Prosetin's Phase 1b ALS trial, reporting strong safety data and target engagement at therapeutic doses.
Buck Institute scientist engineers CAR-Treg cells to detect amyloid plaques and release Alzheimer's antibody exactly where needed.
BioNTech reports positive Phase 2 results for HER2-targeted cancer therapy, with FDA filing planned to compete with existing treatments.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
Northwestern researchers dramatically boosted cancer vaccine effectiveness by simply repositioning one protein fragment on their nanovaccine.
Cyclarity's UDP-003 passed its first human trial with zero serious side effects, successfully flushing toxic 7-ketocholesterol through urine.
